O	0	5	Phase
O	6	7	2
O	8	18	randomized
O	19	24	trial
O	25	27	of
O	28	35	primary
B-intervention	36	45	endocrine
I-intervention	46	53	therapy
O	54	60	versus
B-control	61	73	chemotherapy
O	74	76	in
O	77	91	postmenopausal
O	92	100	patients
O	101	105	with
O	106	114	estrogen
O	115	123	receptor
O	123	124	-
O	124	132	positive
O	133	139	breast
O	140	146	cancer
O	146	147	.

O	148	151	Few
O	152	159	studies
O	160	164	have
O	165	173	compared
O	174	181	primary
O	182	193	neoadjuvant
O	194	203	endocrine
O	204	211	therapy
O	212	216	with
O	217	228	neoadjuvant
O	229	241	chemotherapy
O	242	244	in
O	245	251	breast
O	252	258	cancer
O	259	267	patients
O	267	268	.

O	269	272	The
O	273	277	need
O	278	281	for
O	282	294	preoperative
O	295	307	chemotherapy
O	308	312	with
O	313	324	doxorubicin
O	325	327	or
O	328	335	taxanes
O	336	339	may
O	340	342	be
O	343	350	reduced
O	351	353	in
O	354	368	postmenopausal
O	369	377	patients
O	378	382	with
O	383	391	estrogen
O	392	400	receptor
O	401	402	(
O	402	404	ER
O	404	405	)
O	405	406	-
O	406	414	positive
O	415	418	and
O	418	419	/
O	419	421	or
O	422	434	progesterone
O	435	443	receptor
O	444	445	(
O	445	448	PgR
O	448	449	)
O	449	450	-
O	450	458	positive
O	459	465	tumors
O	465	466	.

O	467	471	This
O	472	482	randomized
O	482	483	,
O	484	494	controlled
O	494	495	,
O	496	501	phase
O	502	503	2
O	504	509	study
O	510	519	evaluated
O	520	523	the
O	524	532	efficacy
O	533	535	of
O	536	547	neoadjuvant
O	548	560	chemotherapy
O	561	569	compared
O	570	574	with
O	575	584	endocrine
O	585	594	treatment
O	595	599	with
O	600	609	aromatase
O	610	620	inhibitors
O	621	623	in
B-eligibility	624	638	postmenopausal
I-eligibility	639	644	women
I-eligibility	645	649	with
I-eligibility	650	652	ER
I-eligibility	652	653	-
I-eligibility	653	661	positive
I-eligibility	662	665	and
I-eligibility	665	666	/
I-eligibility	666	668	or
I-eligibility	669	672	PgR
I-eligibility	672	673	-
I-eligibility	673	681	positive
I-eligibility	682	688	breast
I-eligibility	689	695	cancer
O	695	696	.

O	697	705	Eligible
O	706	714	patients
O	715	719	were
O	720	728	randomly
O	729	737	assigned
O	738	740	to
O	741	748	receive
O	749	760	neoadjuvant
O	761	772	anastrozole
O	773	774	1
O	775	777	mg
O	777	778	/
O	778	781	day
O	782	783	(
O	783	784	n
O	785	786	=
B-intervention-participants	787	789	61
O	789	790	)
O	791	793	or
O	794	804	exemestane
O	805	807	25
O	808	810	mg
O	810	811	/
O	811	814	day
O	815	816	(
O	816	817	n
O	818	819	=
B-control-participants	820	822	60
I-control-participants	822	823	)
O	824	827	for
O	828	829	3
O	830	836	months
O	837	839	or
O	840	851	doxorubicin
O	852	854	60
O	855	857	mg
O	857	858	/
O	858	859	m
O	859	860	(
O	860	861	2
O	861	862	)
O	863	867	with
O	868	878	paclitaxel
O	879	882	200
O	883	885	mg
O	885	886	/
O	886	887	m
O	887	888	(
O	888	889	2
O	889	890	)
O	891	892	(
O	892	896	four
O	897	898	3
O	898	899	-
O	899	903	week
O	904	910	cycles
O	910	911	)
O	911	912	.

O	913	918	Study
O	919	922	end
O	923	929	points
O	930	938	included
B-outcome-Measure	939	946	overall
I-outcome-Measure	947	956	objective
I-outcome-Measure	957	965	response
O	966	976	determined
O	977	979	by
O	980	989	palpation
O	989	990	,
O	991	1002	mammography
O	1002	1003	,
O	1004	1007	and
O	1008	1018	ultrasound
O	1018	1019	,
O	1020	1023	and
O	1024	1027	the
O	1028	1034	number
O	1035	1037	of
O	1038	1046	patients
O	1047	1050	who
O	1051	1060	qualified
O	1061	1064	for
O	1065	1071	breast
O	1071	1072	-
O	1072	1082	conserving
O	1083	1090	surgery
O	1091	1094	and
O	1095	1107	radiotherapy
O	1107	1108	.

B-outcome	1109	1117	Clinical
I-outcome	1118	1127	objective
I-outcome	1128	1136	response
O	1137	1140	was
B-iv-bin-percent	1141	1143	64
I-iv-bin-percent	1143	1144	%
O	1145	1147	in
O	1148	1151	the
O	1152	1161	endocrine
O	1162	1169	therapy
O	1170	1173	and
O	1174	1186	chemotherapy
O	1187	1196	treatment
O	1197	1203	groups
O	1203	1204	.

B-outcome	1205	1211	Median
I-outcome	1212	1216	time
I-outcome	1217	1219	to
I-outcome	1220	1228	clinical
I-outcome	1229	1237	response
O	1238	1241	was
B-iv-cont-median	1242	1244	57
O	1245	1248	and
B-cv-cont-median	1249	1251	51
I-cv-cont-median	1252	1256	days
O	1257	1261	with
O	1262	1271	aromatase
O	1272	1282	inhibitors
O	1283	1286	and
O	1287	1299	chemotherapy
O	1299	1300	,
O	1301	1313	respectively
O	1314	1315	(
O	1315	1316	P
O	1317	1318	>
O	1319	1320	.
O	1320	1322	05
O	1322	1323	)
O	1323	1324	.

O	1325	1330	Rates
O	1331	1333	of
O	1334	1346	pathological
B-outcome	1347	1355	complete
I-outcome	1356	1364	response
O	1365	1366	(
B-iv-bin-percent	1366	1367	3
I-iv-bin-percent	1367	1368	%
O	1369	1371	vs
B-cv-bin-percent	1372	1373	6
I-cv-bin-percent	1373	1374	%
O	1374	1375	)
O	1376	1379	and
B-outcome	1380	1387	disease
I-outcome	1388	1399	progression
O	1400	1401	(
B-iv-bin-percent	1401	1402	9
I-iv-bin-percent	1402	1403	%
O	1404	1406	vs
B-cv-bin-percent	1407	1408	9
I-cv-bin-percent	1408	1409	%
O	1409	1410	)
O	1411	1414	did
O	1415	1418	not
O	1419	1425	differ
O	1426	1439	significantly
O	1440	1442	in
O	1443	1446	the
O	1447	1456	endocrine
O	1457	1464	therapy
O	1465	1467	or
O	1468	1480	chemotherapy
O	1481	1486	group
O	1486	1487	,
O	1488	1500	respectively
O	1501	1502	(
O	1502	1503	P
O	1504	1505	>
O	1506	1507	.
O	1507	1509	05
O	1509	1510	)
O	1510	1511	.

B-outcome	1512	1517	Rates
I-outcome	1518	1520	of
I-outcome	1521	1527	breast
I-outcome	1527	1528	-
I-outcome	1528	1538	conserving
I-outcome	1539	1546	surgery
O	1547	1551	were
O	1552	1560	slightly
O	1561	1567	higher
O	1568	1570	in
O	1571	1574	the
O	1575	1584	endocrine
O	1585	1590	group
O	1591	1592	(
B-iv-bin-percent	1592	1594	33
I-iv-bin-percent	1594	1595	%
O	1596	1598	vs
B-cv-bin-percent	1599	1601	24
I-cv-bin-percent	1601	1602	%
O	1602	1603	;
O	1604	1605	P
O	1606	1607	=
O	1608	1609	.
O	1609	1612	058
O	1612	1613	)
O	1613	1614	.

O	1615	1618	The
O	1619	1623	most
O	1624	1632	frequent
O	1633	1643	toxicities
O	1644	1648	from
O	1649	1661	chemotherapy
O	1662	1666	were
B-outcome	1667	1675	alopecia
O	1676	1677	(
B-cv-bin-percent	1677	1679	79
I-cv-bin-percent	1679	1680	%
O	1680	1681	)
O	1681	1682	,
B-outcome	1683	1688	grade
I-outcome	1689	1690	3
I-outcome	1690	1691	/
I-outcome	1691	1692	4
I-outcome	1693	1704	neutropenia
O	1705	1706	(
B-cv-bin-percent	1706	1708	33
I-cv-bin-percent	1708	1709	%
O	1709	1710	)
O	1710	1711	,
O	1712	1715	and
B-outcome	1716	1721	grade
I-outcome	1722	1723	2
I-outcome	1724	1734	neuropathy
O	1735	1736	(
B-cv-bin-percent	1736	1738	30
I-cv-bin-percent	1738	1739	%
O	1739	1740	)
O	1740	1741	.

O	1742	1751	Endocrine
O	1752	1761	treatment
O	1762	1765	was
B-outcome	1766	1770	well
I-outcome	1771	1780	tolerated
O	1780	1781	.

O	1782	1784	No
B-outcome	1785	1791	deaths
O	1792	1800	occurred
O	1801	1807	during
O	1808	1811	the
O	1812	1824	preoperative
O	1825	1834	treatment
O	1834	1835	.

O	1836	1848	Preoperative
O	1849	1860	neoadjuvant
O	1861	1870	endocrine
O	1871	1878	therapy
O	1879	1883	with
O	1884	1893	aromatase
O	1894	1904	inhibitors
O	1905	1908	was
O	1909	1913	well
O	1914	1923	tolerated
O	1924	1927	and
O	1928	1936	resulted
O	1937	1939	in
O	1940	1945	rates
O	1946	1953	similar
O	1954	1956	to
O	1957	1969	chemotherapy
O	1970	1972	in
O	1973	1980	overall
O	1981	1990	objective
O	1991	1999	response
O	2000	2003	and
O	2004	2010	breast
O	2010	2011	-
O	2011	2021	conserving
O	2022	2029	surgery
O	2030	2032	in
O	2033	2047	postmenopausal
O	2048	2053	women
O	2054	2058	with
O	2059	2061	ER
O	2061	2062	-
O	2062	2070	positive
O	2071	2074	and
O	2074	2075	/
O	2075	2077	or
O	2078	2081	PgR
O	2081	2082	-
O	2082	2090	positive
O	2091	2097	tumors
O	2097	2098	.
